Shots:

• JCR to receive an up front for the Ex-US license & additional development & commercial milestones along with royalties on the sales of JR-141
• Takeda will exclusively commercialize JR-141 outside of the US- including the EU- Canada & other regions (Ex-Japan and other Asia-Pacific countries). Additionally- Takeda has entered into an option agreement under which it receives an option to obtain an exclusive license to commercialize the therapy in the US- following completion of the P-III program
• JR-141 is a recombinant fusion protein of an Ab against human TfR & IDS enzyme. The results from the P-II/III trial demonstrated a reduction in HS in the CSF & improvement in somatic symptoms

  | Ref: Businesswire | Image: The Japan Times